Provides US Food and Drug Administration perspectives on the approval of transcatheter aortic valve replacement devices for patients at low surgical risk.
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: